Literature DB >> 20036713

Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism.

Diane Dufour-Rainfray1, Patrick Vourc'h, Anne-Marie Le Guisquet, Lucette Garreau, David Ternant, Sylvie Bodard, Emilie Jaumain, Zuhal Gulhan, Catherine Belzung, Christian R Andres, Sylvie Chalon, Denis Guilloteau.   

Abstract

In order to explore whether some aspects of the autistic phenotype could be related to impairment of the serotonergic system, we chose an animal model which mimics a potential cause of autism, i.e. rats exposed to valproate (VPA) on the 9th embryonic day (E9). Previous studies have suggested that VPA exposure in rats at E9 caused a dramatic shift in the distribution of serotonergic neurons on postnatal day 50 (PND50). Behavioral studies have also been performed but on rats that were exposed to VPA later (E12.5). Our aim was to test whether VPA exposure at E9 induces comparable behavioral impairments than at E12.5 and causes serotonergic impairments which could be related to behavioral modifications. The results showed significant behavioral impairments such as a lower tendency to initiate social interactions and hyperlocomotor activity in juvenile male rats. The serotonin levels of these animals at PND50 were decreased (-46%) in the hippocampus, a structure involved in social behavior. This study suggests that VPA could have a direct or indirect action on the serotonergic system as early as the progenitor cell stage. Early embryonic exposure to VPA in rats provides a good model for several specific aspects of autism and should help to continue to explore pathophysiological hypotheses. (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036713     DOI: 10.1016/j.neulet.2009.12.054

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  52 in total

1.  Gene-class analysis of expression patterns induced by psychoactive pharmaceutical exposure in fathead minnow (Pimephales promelas) indicates induction of neuronal systems.

Authors:  Michael A Thomas; Parag P Joshi; Rebecca D Klaper
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2011-06-06       Impact factor: 3.228

2.  Downregulating the canonical Wnt/β-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress.

Authors:  Yinghua Zhang; Yan Sun; Fei Wang; Zhongping Wang; Yuwen Peng; Ruixi Li
Journal:  Neurochem Res       Date:  2012-02-29       Impact factor: 3.996

3.  Serotonin neuron abnormalities in the BTBR mouse model of autism.

Authors:  Yue-Ping Guo; Kathryn G Commons
Journal:  Autism Res       Date:  2016-08-01       Impact factor: 5.216

4.  Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats.

Authors:  Ori S Cohen; Elena I Varlinskaya; Carey A Wilson; Stephen J Glatt; Sandra M Mooney
Journal:  Int J Dev Neurosci       Date:  2013-09-19       Impact factor: 2.457

5.  Overexpression of Telomerase Reverse Transcriptase Induces Autism-like Excitatory Phenotypes in Mice.

Authors:  Ki Chan Kim; Jeehae Rhee; Jong-Eun Park; Dong-Keun Lee; Chang Soon Choi; Ji-Woon Kim; Han-Woong Lee; Mi-Ryoung Song; Hee Jeong Yoo; ChiHye Chung; Chan Young Shin
Journal:  Mol Neurobiol       Date:  2015-12-22       Impact factor: 5.590

6.  D-Cycloserine ameliorates social alterations that result from prenatal exposure to valproic acid.

Authors:  Kristen A Wellmann; Elena I Varlinskaya; Sandra M Mooney
Journal:  Brain Res Bull       Date:  2014-08-15       Impact factor: 4.077

Review 7.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

Review 8.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

Review 9.  Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder.

Authors:  Valentina R Garbarino; T Lee Gilman; Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Res       Date:  2018-07-24       Impact factor: 7.658

10.  Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay.

Authors:  Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.